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Encouraged by our previous finding of growth hormone-releasing hormone re-
ceptor (GHRH-R) expression in metaplastic and neoplastic apocrine breast epi-
thelium, we examined a small series of skin adnexal tumours with various degrees 
of apocrine (oxyphilic) differentiation, as well as normal axillary and anogenital 
apocrine sweat glands, for the expression of GHRH-R.
Sections of formalin-fixed paraffin-embedded tissue blocks were immunostained 
for gross cystic disease fluid protein-15 (GCDFP-15) and androgen receptor (AR), 
to prove apocrine differentiation and correlate it with areas of GHRH-R expression.
All but one of 19 tumours with apocrine epithelium and all five benign apocrine 
glands stained with both anti-GHRH-R antibodies used, each labelling a differ-
ent domain of the receptor. Non-apocrine areas of the tumours and four eccrine 
tumours without oxyphilic features did not stain, but most sebaceous glands and 
some eccrine glands were labelled. 
Our data suggest that anti-GHRH-R antibodies highlight apocrine differentia-
tion at extramammary sites also. Although GHRH-R seems to have a sensitivity 
comparable to classic apocrine markers such as AR and GCDFP-15, it seems to be 
inferior in specificity. The GHRH-R labelling of apocrine glands and neoplastic 
epithelium might also interfere with the emerging anti-GHRH targeted treatment 
of some malignancies acting on these receptors.
Key words: skin adnexal tumours, sweat gland, apocrine gland, growth hormone- 
releasing hormone receptor, immunohistochemistry.
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Introduction
Cutaneous adnexal tumours demonstrating 
non-sebaceous glandular differentiation are classified 
as either eccrine or apocrine. By derivation from the 
folliculosebaceous-apocrine unit, gland-forming tu-
mours with a follicular or sebaceous component can 
generally be interpreted as apocrine in the wide sense 
of the word [1]. Apocrine differentiation also means 
a typical phenotype, which is characterised by apical 
snouts (decapitation or apocrine type secretion) and 
a relatively large cytoplasm demonstrating eosino-
philic granularity, although at times only the latter 
is present. This morphology has also been referred 
to as oxyphilic metaplasia. Sometimes the nucle-
us is also rather large, vesicular, with a prominent 
nucleolus visible in it. Typical apocrine glands with 
this morphology include the axillary and anogenital 
sweat glands or the glands of Moll in the ocular re-
gion. A similar morphology is seen in mammary apo-
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crine metaplasia or apocrine differentiation of breast 
neoplasms, which are oestrogen receptor and proges-
terone receptor negative by immunohistochemistry 
(IHC), but show positivity for gross cystic disease 
fluid protein-15 (GCDFP15) and androgen receptors 
(AR) [2].
Growth hormone-releasing hormone (GHRH) 
and its receptors (GHRH-R) have been implicated 
in carcinogenesis both by means of a classical endo-
crine mechanism mediated by growth hormone-in-
duced release of insulin-like growth factor from the 
liver, and as autocrine/paracrine mechanism [3, 4]. In 
a previous IHC-based study, we identified GHRH-Rs 
to be rather uniformly present in apocrine metapla-
sia and carcinomas of the breast [5, 6]. The morpho-
logical similarity of mammary apocrine metaplasia, 
apocrine breast carcinomas, and adnexal tumours 
demonstrating apocrine differentiation (oxyphilic 
metaplasia) prompted us to test for the presence of 
GHRH-R in the latter.
Material and methods
Skin adnexal tumours with apocrine differentia-
tion (oxyphilic metaplasia) and normal anogenital or 
axillary apocrine gland containing tissue blocks were 
identified from the archives of Bács-Kiskun County 
Teaching Hospital and the Pathology Laboratory of 
the Department of Dermatology and Allergology 
of the University of Szeged. Neutral buffered, for-
malin-fixed, and paraffin-embedded archival mate-
rial was used for the study. Apocrine differentiation 
was verified by light microscopy and the presence of 
characteristic morphology of oxyphilic metaplasia, as 
described in the introduction, and was additionally 
proven by immunohistochemistry for GCDFP-15 
and AR (Table I). At least 50% staining was required 
with these latter antibodies. Three to four-microme-
tre-thick sections were immunostained for GHRH-R 
with antibody ab76263 in all cases and with anti-
body PA5-33582 in cases where further slides were 
available (Table I). The ab76263 and PA5-33582 
antibodies recognise the C-terminal (fourth cyto-
plasmic) and the N-terminal (first extracellular) do-
mains of the GHRH-R protein, respectively. A 10% 
cut-off was used to define positive staining with the 
GHRH-R antibodies, as previously described [5, 6]. 
Normal cadaver pituitary tissue was used as positive 
control, and the specimens were evaluated only in the 
case of adequate positivity. 
We also evaluated peritumoural normal sebaceous 
glands, non-apocrine sweat glands, non-apocrine ar-
eas of the tumours showing partial apocrine differ-
entiation, and additionally immunostained 4 eccrine 
sweat gland neoplasms without apocrine differentia-
tion to test the specificity of GHRH-R antibodies as 
an apocrine marker.
Results
Altogether 19 skin adnexal tumours with focal 
to diffuse apocrine differentiation (oxyphilic meta-
plasia), five normal apocrine glands, and four sweat 
gland neoplasms without apocrine differentiation, 
eccrine poroma (n = 2), eccrine cylindroma (n = 2), 
and poroid hidradenoma (n = 1) were analysed. The 
apocrine tumours were diagnosed as apocrine hidro-
cystoma (n = 4), apocrine cystadenoma (n = 2), tu-
bular/papillary apocrine adenoma (n = 3), chondroid 
syringoma (mixed tumour) (n = 4), syringocystad-
enoma papilliferum (n = 3), hidradenoma papil-
liferum (n = 2), and cylindroma (n = 1). All cases 
showed strong GHRH-R positivity in the areas with 
apocrine differentiation using antibody PA5-33582, 
and all but one case (the cylindroma with focal apo-
crine differentiation) were also positive with the an-
tibody ab76263.
Likewise, all five normal axillary or anogenital 
apocrine glands were positive for both GHRH-R an-
tibodies.
Peritumoural sebaceous glands were mostly pos-
itive for both GHRH-R antibodies, but except for 
two cases of normal non-apocrine sweat glands show-
ing partial staining, the remaining eccrine glands, 
Table I. List and applied protocols of primary antibodies
antibOdy name 
(clOne)
immunOgen epitOpe cOmpany dilutiOn incubatiOn  
time/temperature
GHRH-R ab 76263 
(polyclonal)
C-terminal domain 
(50 amino acid)
Abcam  
(Cambridge, UK)
1 : 250 60 min/room 
temperature (RT)
GHRH-R PA5-33582 
(polyclonal)
N-terminal domain 
(18 amino acid)
Thermo Scientific, 
(Waltham, MA, USA)
1 : 600 30 min/RT
AR F39.4.1 Amino acids  
301-320
BioGenex,  
(Fremont, CA, USA)
1 : 50 30 min/RT
GCDFP-15 23A3 Not specified Cell Marque,  
(Rocklin, CA, USA)
1 : 200 30 min/RT
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non-apocrine areas of tumours with partial apocrine 
differentiation and all the four eccrine sweat gland 
neoplasms without apocrine differentiation tested 
were negative.
Discussion
Although apocrine (oxyphilic) differentiation can 
be recognised on haematoxylin and eosin-stained 
slides in most cases, sometimes ancillary studies are 
useful for verification. According to our previous 
findings, GHRH-R is almost universally expressed in 
apocrine lesions of the breast [5, 6]. Encouraged by 
this finding, we analysed the GHRH-R expression of 
normal cutaneous (anogenital and axillary) apocrine 
glands and a small series of cutaneous sweat gland 
neoplasms with apocrine differentiation. GHRH-R 
was expressed in all the normal apocrine glands and 
in the apocrine component of all examined cutaneous 
lesions, suggesting that anti-GHRH-R antibodies 
could be used as an immunohistochemical marker 
of apocrine differentiation. According to our data 
derived from the evaluation of a limited number of 
cases, GHRH-R as an apocrine marker seems to have 
a sensitivity comparable to AR and GCDFP-15. As 
concerns specificity, GHRH-R antibodies are some-
what inferior because other surrounding cutaneous 
tissues, e.g. sebaceous glands and a few eccrine sweat 
Fig. 1. Expression of GHRH-R in normal 
anogenital apocrine glands. A) Typical mor-
phology of dilated apocrine glands (HE); B) 
AR positivity; C) GCDFP-15 positivity; D-E) 
GHRH-R positivity with antibodies ab76263 
(D) and PA5-33582 (E); original magnifica-
tion 20×
A
C
E
B
D
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Fig. 2. Expression of GHRH-R in an apo-
crine tubular/papillary adenoma. A) Typical 
morphology of apocrine differentiation (oxy-
philic metaplasia) (HE); B) AR positivity; 
C) GCDFP-15 positivity (VIP used as chro-
mogen); D-E) GHRH-R positivity with an-
tibodies ab76263 (D) and PA5-33582 (E); 
original magnification 20×
A B
C
E
D
glands, were also positive for this marker. To reduce 
the possibility of non-specific or false staining, we 
selected two primary GHRH-R antibodies, which 
were designed to recognise different domains of the 
GHRH-R protein. Our results on breast carcinomas 
[5, 6] and from this limited series of rare apocrine 
skin adnexal lesions and representative examples of 
normal apocrine structures suggest that GHRH-R 
expression is a relatively uniform, although not ful-
ly specific, feature of normal and neoplastic apocrine 
epithelium.
It is worth noting that GHRH antagonists act-
ing on the GHRH-Rs have been reported to induce 
significant tumour volume reduction in in vitro stud-
ies on triple-negative breast cancer cell lines [7, 8]. 
(Most apocrine breast carcinomas also belong to the 
triple-negative category.) Should anti-GHRH thera-
py become part of clinically used treatments, it could 
be anticipated to target apocrine epithelium at any 
part of the body, and this might manifest as side ef-
fects of the treatment. The presence of GHRH-Rs in 
benign apocrine cutaneous adnexal tumours indicates 
that GHRH-R expression should be also evaluated in 
malignant cutaneous tumours with apocrine differen-
tiation, to allow the remote possibility of a targeted 
anti-GHRH treatment to be explored.
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Fig. 3. Expression of GHRH-R in a cylindroma with focal apocrine differentiation. A) Morphology of the focal apocrine 
differentiation (HE); B) GCDFP-15 positivity (VIP used as chromogen); C) AR positivity; D) GHRH-R positivity with 
antibody PA5-33582 (the case was negative with antibody ab76263); original magnification 20×; inserts 100×
A
C
B
D
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